Vaxart (VXRT) Expected to Announce Quarterly Earnings on Monday

Key Points

• Vaxart is set to report Q1 2026 results after the market close on May 11; analysts expect EPS of $0.02 and revenue of $65.5 million, with conference call details posted on the company’s earnings page.
• In the prior quarter Vaxart sharply beat expectations, reporting EPS of $0.24 versus a consensus of ($0.08) and revenue of $104.24 million versus $35.95 million, yielding a net margin of 6.88% and ROE of 33.83%.
• Shares trade around $0.76 (down 1.6%) with a market cap of about $183.3M, while institutional activity shows notable stake increases by Raymond James, Invesco and Jones Financial, and Wall Street Zen has upgraded the stock to a "buy".

Vaxart (OTCMKTS:VXRT - Get Free Report) is expected to announce its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $65.50 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:30 PM ET.

Vaxart (OTCMKTS:VXRT - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.32. The firm had revenue of $104.24 million for the quarter, compared to analysts' expectations of $35.95 million. Vaxart had a net margin of 6.88% and a return on equity of 33.83%.

Vaxart Trading Down 1.6%

Shares of Vaxart stock traded down $0.01 on Monday, hitting $0.76. 320,586 shares of the company traded hands, compared to its average volume of 704,864. The firm's 50-day simple moving average is $0.70 and its 200 day simple moving average is $0.54. The company has a market cap of $183.29 million, a P/E ratio of 12.63 and a beta of 1.18. Vaxart has a 12-month low of $0.26 and a 12-month high of $0.84.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Vaxart to a "buy" rating in a research report on Friday, January 23rd.

Hedge Funds Weigh In On Vaxart

A number of large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. raised its position in Vaxart by 16.9% in the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company's stock worth $107,000 after purchasing an additional 34,075 shares during the period. Invesco Ltd. raised its position in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 70,568 shares during the period. Creative Planning purchased a new position in Vaxart in the 2nd quarter worth $33,000. Goldman Sachs Group Inc. purchased a new position in Vaxart in the 1st quarter worth $31,000. Finally, Jones Financial Companies Lllp raised its position in Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after purchasing an additional 478,111 shares during the period. Hedge funds and other institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.